Please wait a minute...
European Journal of Gynaecological Oncology  2019, Vol. 40 Issue (5): 744-751    DOI: 10.12892/ejgo4575.2019
Original Research Previous articles | Next articles
Expression of the PI3K/AKT/mTOR pathway as a prognostic factor in patients with advanced high grade serous ovarian carcinoma treated with neoadjuvant chemotherapy
S. Cierniak1, R. Koktysz1, M. Jesiotr1, A. Gąsowska-Bodnar2, L. Bodnar3, *()
1Department of Pathology, Military Institute of Medicine, warsaw, Poland
2Department of Gynecology and Gynecologic Oncology, Military Institute of Medicine, warsaw, Poland
3Department of Oncology, Military Institute of Medicine, warsaw, Poland
Download:  PDF(643KB)  ( 190 ) Full text   ( 7 )
Export:  BibTeX | EndNote (RIS)      
Abstract  

Background: The aim of this study was to search biomarkers in patients with high grade serous ovarian carcinoma (HGSOC) treated with neoadjuvant chemotherapy (NACT) among the components of PI3K/AKT/mTOR pathway. Material and Methods: The authors assessed 49 patients with HGSOC (FIGO IIIC-IV) treated with NACT. The expression of PI3KCA, PTEN, pAKT473, mTOR, and p70S6K were assessed immunohistochemically. Results: The expression of PI3KCA and p70S6K in tumour tissue after NACT was significantly decreased compared to before chemotherapy (p = 0.0005 and p = 0.0256, respectively). Multivariate analysis demonstrated that high mTOR expression, suboptimal range of interval debulking surgery (IDS), platinum resistance, and the lack of paclitaxel in the NACT were independent adverse prognostic factors (HR= 3.86, 95% CI (1.75-8.56); HR= 3.94, 95% CI (1.76-8.83); HR= 2.29, 95% CI (1.13-4.64); and HR= 4.76, 95% CI (1.80-12.59), p < 0.05). Conclusions: The mTOR expression may be an independent prognostic factor, but further investigations are needed.

Key words:  High grade serous ovarian carcinoma      PI3K/AKT/mTOR pathway      Neoadjuvant chemotherapy     
Published:  10 October 2019     
*Corresponding Author(s):  L. BODNAR     E-mail:  lubo@esculap.pl

Cite this article: 

S. Cierniak, R. Koktysz, M. Jesiotr, A. Gąsowska-Bodnar, L. Bodnar. Expression of the PI3K/AKT/mTOR pathway as a prognostic factor in patients with advanced high grade serous ovarian carcinoma treated with neoadjuvant chemotherapy. European Journal of Gynaecological Oncology, 2019, 40(5): 744-751.

URL: 

https://ejgo.imrpress.com/EN/10.12892/ejgo4575.2019     OR     https://ejgo.imrpress.com/EN/Y2019/V40/I5/744

[1] H. Ishibashi, M. Miyamoto, T. Aoyama, H. Soyama, H. Matsuura, H. Iwahashi, M. Takano, K. Furuya. The effect of six scheduled cycles of neoadjuvant chemotherapy on prognosis in advanced ovarian cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(3): 386-390.
[2] Lili Qian, Zhen Shen, Xuefen Zhang, Dabao Wu, Ying Zhou. Fertility-sparing management for bulky cervical cancer with systemic chemotherapy and conization: a case report and review of the literature[J]. European Journal of Gynaecological Oncology, 2019, 40(4): 684-687.
[3] K. Yao, C. Bian, L. Li, Y. Wu, X. Zhao. The clinical response of advanced epithelial ovarian cancer patients to neoadjuvant chemotherapy in China[J]. European Journal of Gynaecological Oncology, 2018, 39(3): 377-380.
[4] H.Y. Xu, Y. Wang, H. Zhang, J. Xu. The long non-coding RNA UCA1, as a prognostic biomarker for high grade serous ovarian carcinoma[J]. European Journal of Gynaecological Oncology, 2017, 38(6): 883-889.
[5] J.Y. Kwack, H.J. Roh, S.G. You, H.J. Cho, S.H. Lee, Y.S. Kwon. Chemotherapy-induced hemolytic uremic syndrome in locally advanced cervical cancer treated with combination chemotherapy after laparoscopic radical hysterectomy: a case report and review of the literature[J]. European Journal of Gynaecological Oncology, 2017, 38(6): 956-959.
[6] E.L. Liu, R.R. Mi, D.H. Wang, L.Q. Wang, Y.M. Zhang, W.M. Chen. Application of combined intraperitoneal and intravenous neoadjuvant chemotherapy in senile patients with advanced ovarian cancer and massive ascites[J]. European Journal of Gynaecological Oncology, 2017, 38(2): 209-213.
[7] A.S. Mousavi, F.S. Hashemi, M.M. Gilani, S. Akhavan, M. Shariat. Clinical efficacy analysis of preoperative neoadjuvant chemotherapy with high-dose dense paclitaxel plus cisplatin in Stages IB2, IIA2, IIB cervical cancer in Iran[J]. European Journal of Gynaecological Oncology, 2016, 37(5): 703-709.
[8] Yuan Yang Yao, Yue Wang, Jian Liu Wang, Chao Zhao, Li Hui Wei. Outcomes of fertility and pregnancy in patients with early-stage cervical cancer after undergoing neoadjuvant chemotherapy[J]. European Journal of Gynaecological Oncology, 2016, 37(1): 109-112.
No Suggested Reading articles found!